The shadow of generic competition has consistently loomed above copyright’s famous drug, PDE5 Inhibitor, triggering questions about the prospects of similar pharmaceutical stakes. While early years saw significant gains, the patent lapse has created the path for less expensive substitutes, possibly reducing revenue and creating a significant haza